The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.

Abstract:

BACKGROUND:Unlike papillary thyroid cancer (PTC), anaplastic thyroid carcinoma (ATC) is extremely aggressive and rapidly lethal without effective therapies. However, the differences of master regulators and regulatory networks between PTC and ATC remain unclear. Methods: Three representative datasets comprising 32 ATC, 69 PTC, and 78 normal thyroid tissue samples were combined to form a large dataset. Differentially expressed genes (DEGs) were identified and enriched by limma package and gene set enrichment analysis, respectively. Subsequently, protein-protein interaction network and transcription factors (TFs) regulatory network were constructed to identify gene modules and master regulators. Further, master regulators were validated by RT-PCR and western blot. Finally, Kaplan-Meier plotter was applied to evaluate their prognostic values. Results: A total of 560 DEGs were identified as ATC-specific malignant signature. The regulatory network analysis showed that nine master regulators were significantly correlated with three gene modules and potentially regulated the expression of DEGs in three gene modules, respectively. Furthermore, CREB3L1, FOSL2, E2F1 and CAT were significantly associated with overall survival of thyroid cancer patients. FOXM1, FOSL2, MYBL2, AVEN and E2F1 were unfavorable factors of recurrence-free survival (RFS), while CAT was a favorable factor of RFS. RT-PCR and western blot confirmed that six TFs were obviously up-regulated in ATC tissues/cell line as compared with PTC and normal thyroid tissues/cell lines, respectively. In addition, 19 ATC-specific kinases were identified to illustrate the potential post-translational modification. Conclusions: Our findings provide a comprehensive insight into malignant mechanism of ATC, which may indicate their value in the future investigation of ATC.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Pan Z,Li L,Qian Y,Ge X,Hu X,Zhang Y,Ge M,Huang P

doi

10.1080/15384047.2020.1803009

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

853-862

issue

9

eissn

1538-4047

issn

1555-8576

journal_volume

21

pub_type

杂志文章
  • Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.

    abstract::Onconase (Onc), a ribonuclease from oocytes or early embryos of Northern Leopard frog (Rana pipiens), is cytostatic and cytotoxic to a variety of tumor lines in vitro, inhibits growth of tumors in animal in vivo models and is currently in Phase IIIb clinical trials for malignant mesothelioma where it displays antitumo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.7.7.6172

    authors: Ita M,Halicka HD,Tanaka T,Kurose A,Ardelt B,Shogen K,Darzynkiewicz Z

    更新日期:2008-07-01 00:00:00

  • A targeted IL-15 fusion protein with potent anti-tumor activity.

    abstract::IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the following 3 parts: (1) IL-15Rα fused with IL-15 to enhance IL-15 activity, (2) an Fc fragment to increase protein half-life, and (3) an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071739

    authors: Chen S,Huang Q,Liu J,Xing J,Zhang N,Liu Y,Wang Z,Li Q

    更新日期:2015-01-01 00:00:00

  • The genetics of FANCC and FANCG in familial pancreatic cancer.

    abstract::Patients with Fanconi anemia (FA) display a wide variety of defects including bone marrow failure and a high risk of developing cancer. Multiple Fanconi genes exist whose proteins form a complex that along with BRCA1 is important for the translocalization of FANCD2 to nuclear foci. With BRCA2 and RAD51, this complex i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.2.609

    authors: Rogers CD,van der Heijden MS,Brune K,Yeo CJ,Hruban RH,Kern SE,Goggins M

    更新日期:2004-02-01 00:00:00

  • Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention.

    abstract::The early observations by Dr Otto Warburg revealed that fundamentally metabolic differences exist between malignant tumor cells and adjacent normal cells. Many studies have further reported the relationship between altered cellular metabolism and therapeutic outcomes. These observations suggest that targeting the pecu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.22958

    authors: Zhang Y,Yang JM

    更新日期:2013-02-01 00:00:00

  • Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.

    abstract:OBJECTIVES:We herein assessed the influence of Epidermal Growth Factor Receptor (EGFR) gene mutations on EGFR expression levels, downstream mediators such as Akt or ERK, and overall survival in patients with ovarian cancer. STUDY DESIGN:EGFR mutation status was analyzed by direct sequencing in 102 Japanese ovarian can...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.1.13877

    authors: Tanaka Y,Terai Y,Tanabe A,Sasaki H,Sekijima T,Fujiwara S,Yamashita Y,Kanemura M,Ueda M,Sugita M,Franklin WA,Ohmichi M

    更新日期:2011-01-01 00:00:00

  • Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.

    abstract::Adverse events in platinum-based chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) are major challenges. In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy. Specifically, we examined the p53 ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.956599

    authors: Zheng D,Chen Y,Gao C,Wei Y,Cao G,Lu N,Hou Y,Jiang X,Wang J

    更新日期:2014-01-01 00:00:00

  • Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines.

    abstract::The aim of this study was to examine the cytotoxicity and mechanism of apoptosis induction of verotoxin-1 (VT-1) in human glioma cell lines. VT-1 is a member of the shiga-toxin family expressed by some serotypes of Escherichia coli and Shigella dysenteriae. Shiga-toxins have been shown to induce apoptosis by binding t...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.9.3173

    authors: Johansson D,Johansson A,Grankvist K,Andersson U,Henriksson R,Bergström P,Brännström T,Behnam-Motlagh P

    更新日期:2006-09-01 00:00:00

  • Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3.

    abstract::We developed a DNA aptamer, Ap52, against the shared tumor-specific MAGE-A3111-125 peptide antigen that was used to target multiple types of cancer cells. Here we report the in vivo study of mice implanted with pancreatic tumor cells AsPC-1, which demonstrates accumulation of phosphorothioate-modified Ap52 (ThioAp52) ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1833156

    authors: Wang CY,Lin BL,Chen CH

    更新日期:2021-01-02 00:00:00

  • C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.

    abstract::Hepatocellular carcinoma (HCC), characterized by a high rate of metastasis and recurrence after surgery, is caused by malignant proliferation of hepatocytes with epigenetic and/or genetic mutations. In particular, abnormal activation of the hepatocyte growth factor (HGF)-/c-mesenchymal-epithelial transition receptor (...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1647051

    authors: Zhao M,Wang Y,Liu Y,Zhang W,Liu Y,Yang X,Cao Y,Wang S

    更新日期:2019-01-01 00:00:00

  • c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells.

    abstract::The novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) induces apoptosis of cancer cells, enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, and exhibits potent anticancer activity in animal models with a favorable pharmacokinetic profile....

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.10.4763

    authors: Zou W,Chen S,Liu X,Yue P,Sporn MB,Khuri FR,Sun SY

    更新日期:2007-10-01 00:00:00

  • Absence of SV40 in Austrian tumors correlates with low incidence of mesotheliomas.

    abstract::Between 1955 and 1963 millions of people were worldwide vaccinated with polio-vaccines that were contaminated with the simian virus 40 (SV40). This tumor-inducing virus has subsequently been detected in several human tumors. In Austria, polio mass vaccination started in winter 1961/62 with a presumably SV40-free Briti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:

    authors: Leithner A,Weinhaeusel A,Windhager R,Schlegl R,Waldner P,Lang S,Dominkus M,Zoubek A,Popper HH,Haas OA

    更新日期:2002-07-01 00:00:00

  • Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.

    abstract::The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1796195

    authors: Handy WF,Schmidt KT,Price DK,Figg WD

    更新日期:2020-09-01 00:00:00

  • Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

    abstract::Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 kinase (PI3K)/Akt/mam...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26725

    authors: Okabe S,Tauchi T,Tanaka Y,Kitahara T,Kimura S,Maekawa T,Ohyashiki K

    更新日期:2014-02-01 00:00:00

  • Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.

    abstract::Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.7.15980

    authors: Paradziej-Łukowicz J,Skwarska A,Peszyńska-Sularz G,Brillowska-Dąbrowska A,Konopa J

    更新日期:2011-10-01 00:00:00

  • Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model.

    abstract::Prostate cancer is the second leading cause of cancer deaths among men. The availability of animal models that represent the events and factors that exist in the natural history and biology of human prostate cancer is essential in dealing with prostate cancer. In recent decades and presently, emphasis has been directe...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.12.18367

    authors: Costello LC,Franklin RB,Zou J,Feng P,Bok R,Swanson MG,Kurhanewicz J

    更新日期:2011-12-15 00:00:00

  • Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.

    abstract::The present studies sought to further understand how the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib interact to kill tumor cells. Sorafenib activated SRC, and via SRC the drug combination activated ERK1/2. Expression of dominant negative SRC or dominant negative MEK1 abolished drug-induced ERK1/2 ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20562

    authors: Bareford MD,Hamed HA,Allegood J,Cruickshanks N,Poklepovic A,Park MA,Ogretmen B,Spiegel S,Grant S,Dent P

    更新日期:2012-07-01 00:00:00

  • Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin.

    abstract::Exosomes released from cancer cells support metastasis and growth of recipient cells and increase their resistance to chemotherapy. Therapeutic targeting of exosomes is a promising area in cancer research. Our aim is to test the effect of the mast cell stabilizer ketotifen on exosomes release from cancer cells and how...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1394544

    authors: Khan FM,Saleh E,Alawadhi H,Harati R,Zimmermann WH,El-Awady R

    更新日期:2018-01-02 00:00:00

  • A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.

    abstract::5-fluorouracil forms classic (covalent, ternary) complexes consisting of thymidylate synthase, fluoro-deoxyuridine monophosphate, and 5,10-methylene tetrahydrofolate. Despite a high pharmacologic interest in the classic complexes formed in cells treated with fluorouracil anticancer agents, the in vivo stability of the...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.8.2976

    authors: Brody JR,Gallmeier E,Yoshimura K,Hucl T,Kulesza P,Canto MI,Hruban RH,Schulick RD,Kern SE

    更新日期:2006-08-01 00:00:00

  • Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer.

    abstract::Chemotherapy in prostate cancer (CaP) even as an adjunct has not been a success. In this communication, we report the pre-clinical efficacy of a nitroacridine derivative, C-1748 (9[2'-hydroxyethylamino]-4-methyl-1-nitroacridine) in CaP cell culture and human xenograft animal models. C-1748, a DNA intercalating agent h...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.10.4790

    authors: Tadi K,Ashok BT,Chen Y,Banerjee D,Wysocka-Skrzela B,Konopa J,Darzynkiewicz Z,Tiwari RK

    更新日期:2007-10-01 00:00:00

  • STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.

    abstract::The six-transmembrane epithelial antigen of prostate 2 (STEAP2) protein was identified in advanced prostate cancer, and is highly over-expressed in various types of cancer. This study aimed to investigate the prognostic value and the function of STEAP2 in breast cancer. STEAP2 mRNA and protein expressions in breast no...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1685290

    authors: Yang Q,Ji G,Li J

    更新日期:2020-01-01 00:00:00

  • Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.

    abstract::Alterations in the function of cell cycle checkpoints are frequently detected in oral squamous cell carcinomas (OSCCs), and are often associated with the sensitivity of the cancer cells to chemotherapeutic drugs. Recently, a mitotic checkpoint gene, Chfr, was shown to be inactivated by promoter methylation and point m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.7.1896

    authors: Ogi K,Toyota M,Mita H,Satoh A,Kashima L,Sasaki Y,Suzuki H,Akino K,Nishikawa N,Noguchi M,Shinomura Y,Imai K,Hiratsuka H,Tokino T

    更新日期:2005-07-01 00:00:00

  • Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines.

    abstract::TPCK is widely used as an inhibitor of chymotrypsin-like proteases but has recently been identified as an inhibitor of the PDK1/Akt pathway. In this study, we show that TPCK inhibits TRAIL-induced caspase activity but potentiates wortmannin-dependent caspase activity in prostatic carcinoma cell lines. The inhibitory a...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.8.970

    authors: Rokhlin OW,Guseva NV,Taghiyev AF,Glover RA,Cohen MB

    更新日期:2004-08-01 00:00:00

  • Tumor suppressor activities of the Fbw7 E3 ubiquitin ligase receptor.

    abstract::The F-box protein Fbw7/Sel-10/hCdc4/Ago, which is known to regulate ubiquitination and degradation of numerous important regulators of cell division and death including Notch, cyclin E, c-Jun and c-Myc, has been recently rediscovered as a p53-dependent tumor suppressor. Delineation of the mechanisms of Fbw7 anti-oncog...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.4.5.1703

    authors: Fuchs SY

    更新日期:2005-05-01 00:00:00

  • Associations between genetic polymorphisms in interleukin-10 and hematological oncology: evidence from a meta-analysis.

    abstract::Background: Associations between polymorphisms in interleukin-10 (IL-10) and hematological oncology were already explored by many genetic association studies, with controversial findings. The aim of this meta-analysis was to more comprehensively analyze associations between polymorphisms in IL-10 and hematological onc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1702404

    authors: Hong P,Feng WY,Fu LH,Jin J,Fu JP

    更新日期:2020-04-02 00:00:00

  • Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy.

    abstract::Cancer-testis antigens (CTAs) are often specifically expressed in cancer cells and under normal conditions are only considered to be expressed in the germ line cells and the placenta. CTAs are potential targets for cancer immunotherapy and therefore necessitates their expression profiling. The expression profile of LA...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.3.15949

    authors: Forghanifard MM,Gholamin M,Farshchian M,Moaven O,Memar B,Forghani MN,Dadkhah E,Naseh H,Moghbeli M,Raeisossadati R,Abbaszadegan MR

    更新日期:2011-08-01 00:00:00

  • Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma.

    abstract::Drug resistance has always been the main problem in osteosarcoma treatment, and hypoxia seems to be one of the many causes for drug resistance. Therefore, in this study, we investigated how hypoxia triggers chemotherapy resistance in osteosarcoma. We first screened hypoxia- and normoxia- cultured osteosarcoma cells in...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1294285

    authors: Ma Q,Zhang Y,Liu T,Jiang K,Wen Y,Fan Q,Qiu X

    更新日期:2017-03-04 00:00:00

  • Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies.

    abstract::Dendritic cells (DC) operate through an immature (iDC) step (where tumor antigens are internalized) and a mature step (mDC) (where tumor antigens (TA) are cross-presented to naive TA-specific cytotoxic T lymphocyte (CTL) progenitors). Receptors by which cellbound antigens can access the DC cross-presentation pathway i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.12.4973

    authors: Signorino E,Brusa D,Granata R,Malavasi F,Ferrone S,Matera L

    更新日期:2007-12-01 00:00:00

  • Antagonistic drug combinations that select against drug resistance: from bacteria to cancer.

    abstract::Any drug selects for drug resistance. But super-antagonistic drug combinations can select for drug sensitivity. This has important application not only for antibacterial therapy but also for cancer therapy: to control cancer with lesser side effects and to eliminate drug-resistant cancer cells, while sparing sensitive...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.7.4340

    authors: Blagosklonny MV

    更新日期:2007-07-01 00:00:00

  • Histone, H1.2: another housekeeping protein that kills.

    abstract::Histone H1.2, a housekeeping protein that binds nucleosomal linkers, has recently been identified as an apoptogenic factor released from the nucleus to the cytosol in response to double strand DNA breaks. In the cytosol, it promotes the activation of proapoptotic Bcl-2 family proteins, mitochondrial cytochrome c relea...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.1.738

    authors: Zong WX

    更新日期:2004-01-01 00:00:00

  • Managing bone complications of solid tumors.

    abstract::Bone metastases are a common occurrence in patients with breast cancer, lung cancer and prostate cancer. Bone metastases cause considerable morbidity including pain, impaired mobility, pathologic fracture, spinal cord or nerve root compression, bone marrow infiltration and hypercalcemia of malignancy. These complicati...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.5.9.3308

    authors: Berenson JR,Rajdev L,Broder M

    更新日期:2006-09-01 00:00:00